Mucosa Science Hub

The healthcare sector is undergoing a significant transformation, driven by an enhanced understanding of the mucosa, skin and microbiome’s role in  health & disease.

cancer Cancer Toxicity Support

Oral mucositis (OM) is a frequent and debilitating complication of cancer therapy, affecting up to 90% of head and neck cancer patients and all stem cell transplant recipients. Caused by toxicity to the mucosa barrier from chemotherapy and/or radiotherapy, OM often results in treatment delays and worsened outcomes. 

With limited safe and effective treatments available, current research is focused on developing non-invasive, evidence-based therapies to preserve mucosa integrity and enhance patient resilience during cancer care.

Oral mucositis (OM) is a frequent and debilitating complication of cancer therapy, affecting up to 90% of head and neck cancer patients and all stem cell transplant recipients. Caused by toxicity to the mucosa barrier from chemotherapy and/or radiotherapy, OM often results in treatment delays and worsened outcomes. 

With limited safe and effective treatments available, current research is focused on developing non-invasive, evidence-based therapies to preserve mucosa integrity and enhance patient resilience during cancer care.

cancer Women’s Health

Estrogen deficiency—whether due to menopause or breast cancer therapy—can significantly compromise genitourinary mucosal health. Conditions like vulvovaginal atrophy (VVA) and genitourinary syndrome of menopause (GSM) are prevalent and often go untreated, particularly when hormone-based therapies are not an option.

With an emphasis on addressing mucosa side effects resulting from estrogen suppression in breast cancer treatment, aiming to improve quality of life and adherence to therapy with safe, non-hormonal, and clinically validated solutions to support mucosal wellness in these populations.

Estrogen deficiency—whether due to menopause or breast cancer therapy—can significantly compromise genitourinary mucosal health. Conditions like vulvovaginal atrophy (VVA) and genitourinary syndrome of menopause (GSM) are prevalent and often go untreated, particularly when hormone-based therapies are not an option.

With an emphasis on addressing mucosa side effects resulting from estrogen suppression in breast cancer treatment, aiming to improve quality of life and adherence to therapy with safe, non-hormonal, and clinically validated solutions to support mucosal wellness in these populations.

cancer Microbiome-Driven Inflammation

Microbiome imbalance has been increasingly linked to immune perturbation and low-grade chronic inflammation. Loss of microbial diversity contributes to a sustained pro-inflammatory state, playing a role in various local and systemic diseases, including obesity.

Active clinical trials are investigating microbiome modulation as a strategy to reduce inflammation and restore immune homeostasis, offering new therapeutic potential in managing inflammation-driven conditions.

Microbiome imbalance has been increasingly linked to immune perturbation and low-grade chronic inflammation. Loss of microbial diversity contributes to a sustained pro-inflammatory state, playing a role in various local and systemic diseases, including obesity.

Active clinical trials are investigating microbiome modulation as a strategy to reduce inflammation and restore immune homeostasis, offering new therapeutic potential in managing inflammation-driven conditions.